Viridian Therapeutics (VRDN)

• Market cap: $2.18B
• 1 day: -2.28%
• 5 days: 1.75%
• 1 month: 25.17%
• 3 months: 32.04%
• 6 months: -39.39%
• Year to date: -35.66%
• 1 year: 15.24%
• 5 years: 8.46%
• 10 years: -82.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Employees: 252